LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Kura Oncology Inc

Fechado

SetorSaúde

6.01 1.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.88

Máximo

6.2

Indicadores-chave

By Trading Economics

Rendimento

-38M

-57M

Vendas

-40M

14M

EPS

-0.66

Margem de lucro

-407.067

Funcionários

192

EBITDA

-48M

-65M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+279.83% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.4M

527M

Abertura anterior

4.49

Fecho anterior

6.01

Sentimento de Notícias

By Acuity

50%

50%

177 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de mai. de 2025, 19:39 UTC

Grandes Movimentos do Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 de mai. de 2025, 23:18 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 de mai. de 2025, 22:30 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- Update

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de mai. de 2025, 21:54 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 de mai. de 2025, 21:22 UTC

Conversa de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 de mai. de 2025, 21:17 UTC

Conversa de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 de mai. de 2025, 21:17 UTC

Principais Notícias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 de mai. de 2025, 21:05 UTC

Conversa de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 de mai. de 2025, 20:55 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de mai. de 2025, 20:37 UTC

Principais Notícias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 de mai. de 2025, 20:33 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 de mai. de 2025, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 de mai. de 2025, 20:18 UTC

Principais Notícias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 de mai. de 2025, 20:16 UTC

Principais Notícias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 de mai. de 2025, 20:15 UTC

Ganhos

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 de mai. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: William K. Daniel Joins Board

16 de mai. de 2025, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: Strategic Investment by KKR Completed

16 de mai. de 2025, 20:05 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 19:38 UTC

Conversa de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 de mai. de 2025, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 de mai. de 2025, 18:51 UTC

Principais Notícias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 de mai. de 2025, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 18:37 UTC

Conversa de Mercado

Gold Futures End Week on Negative Note -- Market Talk

16 de mai. de 2025, 18:35 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 de mai. de 2025, 18:32 UTC

Principais Notícias

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 de mai. de 2025, 18:28 UTC

Conversa de Mercado

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

279.83% parte superior

Previsão para 12 meses

Média 22.6 USD  279.83%

Máximo 40 USD

Mínimo 10 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

10

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

177 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.